Gene study aims to sharpen malaria pill dosing
NCT ID NCT07373743
First seen Feb 01, 2026 · Last updated Jun 09, 2026 · Updated 18 times
Summary
This study looks at how different genetic makeups affect the way healthy adults process the malaria prevention drug tafenoquine (ARAKODA). Researchers will measure drug levels in blood and urine over time, along with safety checks. The goal is to better understand how to dose the drug for different people. The study involves 20 healthy adults aged 18-65.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETIC IN NORMAL POPULATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SUNY Upstate Medical University, Upstate Global Health Institute
East Syracuse, New York, 13057, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.